Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase EARLY_PHASE1 1Phase 4 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colonic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Specimen Handling 17Radiotherapy 17Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11Fluorodeoxyglucose F18 10fludarabine 9X-Rays 9Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4olaparib 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Tea × 1 year × Clear all
NCT02891538 2025-09-04

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

The University of Texas Health Science Center at San Antonio

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡